Evidence map›Paper›PMID 40810286›Full record

SynthesisJournal of comparative effectiveness research2025

Evaluation of the efficacy and cost-effectiveness of safinamide versus rasagiline: a systematic review.

Antonio J García Ruiz, Ester Morales García, María José Gómez Heredia, Francisco Pérez Errazquin, Nuria García-Agua Soler

Abstract readSystematic Review
In one paragraph

Synthesis in Journal of comparative effectiveness research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Antonio J García RuizDepartment of Pharmacology & Pediatrics, School of Medicine, University of Malaga, Biomedical Research Institute of Malaga (IBIMA-Bionand), Malaga, Spain.ORCID 0000-0001-6423-6993
Ester Morales GarcíaDepartment of Neurology, Hospital Universitario Virgen de la Victoria, Málaga, Spain.
María José Gómez HerediaDepartment of Neurology, Hospital Universitario Virgen de la Victoria, Málaga, Spain.
Francisco Pérez ErrazquinDepartment of Neurology, Hospital Universitario Virgen de la Victoria, Málaga, Spain.
Nuria García-Agua SolerDepartment of Pharmacology & Pediatrics, School of Medicine, University of Malaga, Biomedical Research Institute of Malaga (IBIMA-Bionand), Malaga, Spain.ORCID 0000-0003-2979-5241

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

AlanineAntiparkinson AgentsBenzylaminesIndansParkinson DiseaseCost-Benefit AnalysisHumansRandomized Controlled Trials as TopicTreatment OutcomeAlanineAntiparkinson AgentsBenzylaminesIndansrasagilinesafinamideadjuvantcostsefficacyefficiencyParkinson’s diseasepharmacoeconomyrasagilinesafinamide

Identifiers

PMID40810286
PMCPMC12403354

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.